Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Timothy Kyin

Allergy & Immunology Charlottesville, VA Medical Doctor

NPI 1548381866 CMS profile 1062084

2955 Ivy Rd, Ste 311, Charlottesville, VA 22903

Open in the dashboard

General payments

$1,426

7 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Timothy Kyin of Charlottesville, VA is reported in the CMS Open Payments database as having received $1,426 across 7 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 45th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $244 3
2019 General $1,182 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Timothy Kyin
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Timothy Kyin were reported at $244. Among 336 Allergy & Immunology profiles paid that year, the median was $682 and the middle half received between $143 and $2,317.

Show as a table
Year Timothy Kyin Allergy & Immunology median Middle half National median
2019 $1,182 $378 $115–$1,178 $163
2020 $0 $303 $75–$1,581 $114
2021 $0 $407 $122–$1,475 $132
2022 $0 $357 $120–$1,340 $149
2023 $0 $445 $124–$1,536 $160
2024 $0 $541 $129–$1,763 $164
2025 $244 $682 $143–$2,317 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $1,152 3 payments
  2. ARS Pharmaceuticals Operations, Inc. $134 1 payment
  3. GlaxoSmithKline, LLC. $89 1 payment
  4. Genentech USA, Inc. $29 1 payment
  5. AstraZeneca Pharmaceuticals LP $23 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $1,053 1 payment
  2. Food and Beverage $373 6 payments
Products named General payments · program years 2019–2025
  1. NO PRODUCT DISCUSSED $1,131 2 payments
  2. NEFFY $134 1 payment
  3. NUCALA $89 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

406

Median for Allergy/ Immunology: 449

Drug cost

$736,287

Median for Allergy/ Immunology: $169,700

Branded share of claims

40.9%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Orladeyo Berotralstat Hydrochloride Brand 14 $576,517
Nucala Mepolizumab Brand 16 $83,700
Dupixent Syringe Dupilumab Brand 14 $51,963
Breo Ellipta Fluticasone/Vilanterol Brand 21 $9,964
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 36 $3,871
Epinephrine Generic 18 $3,451
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 26 $3,050
Wixela Inhub Fluticasone Propion/Salmeterol Brand 12 $1,094
Montelukast Sodium Generic 118 $1,036
Azelastine Hcl Generic 30 $703

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$33,719

Medicare's payments for the services billed

Medicare patients

253

Average age 72

Services billed

1,729

173 women, 80 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 55%
Ischemic heart disease 23%
Depression 22%
Chronic kidney disease 20%
Osteoporosis 19%
COPD 18%
Diabetes 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

7 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record